A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases (original) (raw)

Leukemia volume 25, pages 557–560 (2011)Cite this article

Subjects

Blast crisis (BC) is the terminal phase of chronic myeloid leukemia (CML) and is characterized by a rapid expansion of myeloid or lymphoid differentiation-arrested blast cells leading to short median survival.1, 2 In approximately 70% of cases the blast lineage is myeloid, whereas in 20–30% of cases the blasts are lymphoid.3 It has been suggested that the progression of CML to BC-CML is a two-step process. The initial step for chronic phase is the occurrence of the Philadelphia chromosome and genetic instability caused by the BCR–ABL tyrosine kinase.4 The second step is the acquisition of additional chromosomal aberrations or mutations of transcription factors by failed DNA repair processes.5 However, at present, little is known about the molecular mechanisms underlying disease progression, but, most likely, activation of oncogenic factors and/or mutations leading to loss of function of tumor suppressor genes in hematopoietic stem cells are involved.2 Only limited changes occurring during clonal evolution of chronic phase to BC, both resulting in altered gene expression patterns or DNA copy number alterations, have been described. We hypothesized that specific molecular alterations that regulate gene transcription occurring in other myeloid and lymphatic malignancies may be acquired during the malignant disease progression from chronic phase to BC.

In this study, in total, 39 BC-CML cases (_n_=24 myeloid, _n_=10 lymphoid, _n_=5 not specified) were analyzed to elucidate the molecular mechanisms underlying disease progression. Between September 2005 and July 2009, cells were collected from the purified fraction of mononuclear cells after Ficoll density centrifugation. With respect to the karyotype, 12/34 cases analyzed (38.2%) harbored a t(9;22) translocation chromosome without additional chromosomal aberrations at BC-CML stage (cytogenetic data not available in five cases), whereas the other 22 cases carried additional alterations such as +8, +Philadelphia, +19, i(17)(q10), −7 and inv(3)(q21q26) (Table 1).

Table 1 Chromosomal and molecular aberrations in 39 BC-CML cases

Full size table

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$259.00 per year

only $21.58 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Figure 1

References

  1. Perrotti D, Jamieson C, Goldman J, Skorski T . Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010; 120: 2254–2264.
    Article CAS PubMed PubMed Central Google Scholar
  2. Calabretta B, Perrotti D . The biology of CML blast crisis. Blood 2004; 103: 4010–4022.
    Article CAS PubMed Google Scholar
  3. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. Myeloproliferative neoplasms. WHO Classification of Tumours of Haematopoietic and Lympoid Tissues. IARC: Lyon, France, 2008.
    Google Scholar
  4. Burke BA, Carroll M . BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia. Leukemia 2010; 24: 1105–1112.
    Article CAS PubMed PubMed Central Google Scholar
  5. Zhang S . The role of aberrant transcription factor in the progression of chronic myeloid leukemia. Leuk Lymphoma 2008; 49: 1463–1469.
    Article PubMed Google Scholar
  6. Iacobucci I, Storlazzi CT, Cilloni D, Lonetti A, Ottaviani E, Soverini S et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 2009; 114: 2159–2167.
    Article CAS PubMed Google Scholar
  7. Abdel-Wahab O, Kilpivaara O, Patel J, Busque L, Levine RL . The most commonly reported variant in ASXL1 (c.1934dupG; p.Gly646TrpfsX12) is not a somatic alteration. Leukemia 2010; 24: 1656–1657.
    Article CAS PubMed PubMed Central Google Scholar
  8. Miething C, Grundler R, Mugler C, Brero S, Hoepfl J, Geigl J et al. Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment. Proc Natl Acad Sci USA 2007; 104: 4594–4599.
    Article CAS PubMed PubMed Central Google Scholar

Download references

Author information

Authors and Affiliations

  1. MLL Munich Leukemia Laboratory, Munich, Germany
    V Grossmann, A Kohlmann, M Zenger, S Schindela, C Eder, S Weissmann, S Schnittger, W Kern, T Haferlach & C Haferlach
  2. III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany
    M C Müller
  3. Abteilung Hämatologie und Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany
    A Hochhaus

Authors

  1. V Grossmann
    You can also search for this author inPubMed Google Scholar
  2. A Kohlmann
    You can also search for this author inPubMed Google Scholar
  3. M Zenger
    You can also search for this author inPubMed Google Scholar
  4. S Schindela
    You can also search for this author inPubMed Google Scholar
  5. C Eder
    You can also search for this author inPubMed Google Scholar
  6. S Weissmann
    You can also search for this author inPubMed Google Scholar
  7. S Schnittger
    You can also search for this author inPubMed Google Scholar
  8. W Kern
    You can also search for this author inPubMed Google Scholar
  9. M C Müller
    You can also search for this author inPubMed Google Scholar
  10. A Hochhaus
    You can also search for this author inPubMed Google Scholar
  11. T Haferlach
    You can also search for this author inPubMed Google Scholar
  12. C Haferlach
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toV Grossmann.

Ethics declarations

Competing interests

CH, S Schnittger, WK, and TH have equity ownership of MLL Munich Leukemia Laboratory. VG, AK, MZ, CE, S Schindela, and SW are employed by MLL Munich Leukemia Laboratory. MCM and AH declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Leukemia website

Supplementary information

Rights and permissions

About this article

Cite this article

Grossmann, V., Kohlmann, A., Zenger, M. et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases.Leukemia 25, 557–560 (2011). https://doi.org/10.1038/leu.2010.298

Download citation